QUELL THERAPEUTICS: ASTRAZENECA EXERCISED ITS EXCLUSIVE OPTION TO LICENSE POTENTIAL THERAPY, RESULTING IN PAYMENT TO QUELL OF $10 MLN

Reuters · 06/10 11:10

Please log in to view news